| Next 10 |
Ad
OCGN Articles Ocugen Inc.
home / stock / ocgn / ocgn articles
Articles | Ocugen, Inc. (NASDAQ:OCGN)
-
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday. Shares of Vanda Pharmaceuticals Inc. (N...
-
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen...
-
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds invest...
-
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds invest...
-
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen...
-
ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (N...
-
BENSALEM, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on ...
-
LOS ANGELES, May 30, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 10, 2024 deadline ...
-
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen,...
Stock Information
Get OCGN Alerts
News, Short Squeeze, Breakout and More Instantly...
Ocugen, Inc. Company Name:
OCGN Stock Symbol:
NASDAQ Market:
-1.47% G/L:
$0.5373 Last:
2,732,951 Volume:
$0.5505 Open:
$0.5373 Close:
Ocugen, Inc. Website:
Ad
-
2025-03-05 13:15:17 ET Image source: The Motley Fool. Ocugen (NASDAQ: OCGN) Q4 2024 Earnings Call Mar 05, 2025 , 8:30 a.m. ET Operator Continue reading
-
Kodiak Gas Services Inc. (KGS) is expected to report $0.26 for Q4 2024 Kronos Worldwide Inc (KRO) is expected to report $0.11 for Q4 2024 Neonode Inc. (NEON) is expected to report for Q4 2024 Applied Therapeutics Inc. (APLT) is expected to report $-0.18 for Q4 2024 Churchill Capit...
-
100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years 100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only performed up to one ...
Important Investor News Alert (OTC: AVAI)
-
LAS VEGAS, NV / ACCESS Newswire / March 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), tod...